Need professional-grade analysis? Visit stockanalysis.com
$12.23B
21.81
2,635
2.06%
Pacific Shuanglin Bio pharmacy Co Ltd (000403) trades on SHE in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY12.91, down 1.15% from the previous close.
Over the past year, 000403 has traded between a low of CNY12.67 and a high of CNY18.89. The stock has lost 24.3% over this period. It is currently 31.7% below its 52-week high.
Pacific Shuanglin Bio pharmacy Co Ltd has a market capitalization of $12.23B, with a price-to-earnings ratio of 21.81 and a dividend yield of 2.06%.
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepatitis B human immunoglobulin (pH4). In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; electronic product information consultation; trading; technology application; and technical services activities. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.
Side-by-side comparison against top Healthcare peers.